Phase 1 Study of first-in-class dUTPase inhibitor, TAS-114 in combination with capecitabine in patients with advanced solid tumors. (December 2016) - LoRusso, P.; Miller, K.; Shields, A.; Saito, K.; Yoshida, K.; Aoyama, T.; Winkler, R.; Benedetti, F.; Lenz, H.J.